Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 97.49% from the company's current price.

YMAB has been the topic of several other research reports. Canaccord Genuity Group restated a "buy" rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a "strong-buy" rating in a research report on Tuesday, August 13th. BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 13th. Wedbush restated an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Finally, Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.14.

Y-mAbs Therapeutics Price Performance

YMAB traded down $0.45 during midday trading on Friday, hitting $11.14. 699,093 shares of the company's stock traded hands, compared to its average volume of 242,513. The stock's fifty day simple moving average is $13.98 and its 200-day simple moving average is $13.08. Y-mAbs Therapeutics has a one year low of $5.04 and a one year high of $20.90. The company has a market cap of $498.96 million, a PE ratio of -20.63 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same period in the prior year, the company posted ($0.18) EPS. On average, research analysts expect that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insider Activity

In related news, COO Joris Wilms sold 5,000 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company's stock, valued at $449,514. This trade represents a 14.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares of the company's stock, valued at $1,315,763.07. This represents a 39.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,000 shares of company stock worth $1,338,100. Company insiders own 22.50% of the company's stock.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds have recently modified their holdings of YMAB. Ameritas Investment Partners Inc. raised its stake in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company's stock worth $60,000 after buying an additional 1,056 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company's stock valued at $345,000 after acquiring an additional 1,657 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Y-mAbs Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company's stock valued at $993,000 after purchasing an additional 2,760 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth $44,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock worth $113,000 after purchasing an additional 3,416 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.